This company listing is no longer active
ENDPQ N Stock Overview
A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Endo International plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$169.00 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 1.59 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | 39.67% |
| 5 Year Change | 27.40% |
| Change since IPO | 45.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| ENDPQ N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -2.3% | 1.1% |
| 1Y | n/a | -11.8% | -5.2% |
Return vs Industry: Insufficient data to determine how ENDPQ N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ENDPQ N performed against the MX Market.
Price Volatility
| ENDPQ N volatility | |
|---|---|
| ENDPQ N Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in MX Market | 8.9% |
| 10% least volatile stocks in MX Market | 2.8% |
Stable Share Price: ENDPQ N has not had significant price volatility in the past 3 months.
Volatility Over Time: ENDPQ N's weekly volatility (0%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 3,103 | Blaise Coleman | www.endo.com |
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren’s contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company’s Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections.
Endo International plc Fundamentals Summary
| ENDPQ N fundamental statistics | |
|---|---|
| Market cap | Mex$347.86m |
| Earnings (TTM) | -Mex$58.31b |
| Revenue (TTM) | Mex$46.21b |
0.0x
P/S Ratio0.0x
P/E RatioIs ENDPQ N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENDPQ N income statement (TTM) | |
|---|---|
| Revenue | US$2.55b |
| Cost of Revenue | US$1.09b |
| Gross Profit | US$1.47b |
| Other Expenses | US$4.69b |
| Earnings | -US$3.22b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.70 |
| Gross Margin | 57.42% |
| Net Profit Margin | -126.20% |
| Debt/Equity Ratio | -203.3% |
How did ENDPQ N perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/02 13:47 |
| End of Day Share Price | 2023/02/28 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Endo Inc. is covered by 45 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Silver | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| Sumant Satchidanand Kulkarni | BofA Global Research |